Xencor (XNCR) Stock Price, News & Analysis

Company Overview

Xencor, Inc. is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies and cytokine therapeutics for cancer, autoimmune diseases and other serious medical conditions. The company’s research is based largely on its XmAb technology platform, which is designed to modify antibody structures to improve immune-system activity, extend drug half-life or enable the simultaneous targeting of multiple biological pathways.

Xencor’s pipeline includes investigational therapies intended to engage immune cells, regulate immune responses and target tumor-associated proteins. Its programs have included bispecific antibodies and cytokine-based medicines for oncology and immunology applications. Xencor has also entered into collaborations and licensing arrangements with larger pharmaceutical companies to develop and commercialize medicines incorporating its antibody-engineering technologies. Tafasitamab, marketed as Monjuvi in the United States, is one example of a commercial product developed using Xencor’s technology.

Founded in 1997 and headquartered in Monrovia, California, Xencor conducts research and development primarily in the United States while working with commercial and development partners serving international markets. John Desjarlais, Ph.D., serves as the company’s president and chief executive officer. Xencor’s business model combines internal drug development with partnerships intended to broaden the application of its XmAb platform.

Key Stats

• Today's Range: $24.35 to $25.38
• 50-Day Range: $19.40 to $29.30
• 52-Week Range: $10.38 to $30.61
• Volume: 1.15 million shs
• Average Volume: 1.52 million shs
• Market Capitalization: $1.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.00
• Consensus Rating: Moderate Buy

Xencor Stock Analysis - MarketRank™

Xencor scored higher than 36% of companies evaluated by MarketBeat, and ranked 723rd out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Xencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Xencor has a consensus price target of $34.00, representing about 38.0% upside from its current price of $24.63.

Amount of Analyst Coverage

Xencor has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Xencor are expected to decrease in the coming year, from ($3.05) to ($3.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xencor is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xencor is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xencor has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.19% of the float of Xencor has been sold short.

Short Interest Ratio / Days to Cover

Xencor has a short interest ratio ("days to cover") of 10.11, which indicates bearish sentiment.

Change versus previous month

Short interest in Xencor has recently increased by 3.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xencor does not currently pay a dividend.

Dividend Growth

Xencor does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.90

News Sentiment

Xencor has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Xencor this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xencor insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.08% of the stock of Xencor is held by insiders.

Percentage Held by Institutions

Xencor has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XNCR
• CIK: 1326732
• Web: www.xencor.com
• Phone: (626) 305-5900
• Fax: 626-305-0350
• Employees: 260
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Xencor: $34.00
• High Price Target: $55.00
• Low Price Target: $20.00
• Potential Upside/Downside: +38.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$91.92 million
• Net Margins: -155.59%
• Pretax Margin: -153.23%
• Return on Equity: -28.66%
• Return on Assets: -20.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.39

Sales & Book Value

• Annual Sales: $125.58 million
• Price / Sales: 14.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.90 per share
• Price / Book: 2.77

Miscellaneous

• Outstanding Shares: 74,350,000
• Free Float: 70,576,000
• Market Cap: $1.83 billion
• Optionable: Optionable
• Beta: 0.89